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Processing of oat: the impact on oat’s cholesterol
lowering eﬀect
Myriam M.-L. Grundy, a Anthony Fardet, b Susan M. Tosh, c Gillian T. Richa
and Peter J. Wilde *a
Epidemiological and interventional studies have clearly demonstrated the beneﬁcial impact of consuming
oat and oat-based products on serum cholesterol and other markers of cardiovascular disease. The
cholesterol-lowering eﬀect of oat is thought to be associated with the β-glucan it contains. However, not
all food products containing β-glucan seem to lead to the same health outcome. Overall, highly pro-
cessed β-glucan sources (where the oat tissue is highly disrupted) appear to be less eﬀective at reducing
serum cholesterol, but the reasons are not well understood. Therefore, the mechanisms involved still
need further clariﬁcation. The purpose of this paper is to review current evidence of the cholesterol-low-
ering eﬀect of oat in the context of the structure and complexity of the oat matrix. The possibility of a
synergistic action and interaction between the oat constituents promoting hypocholesterolaemia is also
discussed. A review of the literature suggested that for a similar dose of β-glucan, (1) liquid oat-based
foods seem to give more consistent, but moderate reductions in cholesterol than semi-solid or solid
foods where the results are more variable; (2) the quantity of β-glucan and the molecular weight at
expected consumption levels (∼3 g day−1) play a role in cholesterol reduction; and (3) unreﬁned β-glucan-
rich oat-based foods (where some of the plant tissue remains intact) often appear more eﬃcient at lower-
ing cholesterol than puriﬁed β-glucan added as an ingredient.
1. Introduction
It is widely recognized that the intake of dietary fibre in a
typical Western diet is below recommendations. Oat is one of
several grains eaten as part of a Western diet but its consump-
tion and global production are much lower compared to the
staple crops wheat, maize, rice, and barley.1 One of the
reasons for its low global production could be a lack of diver-
sity in the oat products commercially available. However,
studies reveal the multiple beneficial eﬀects on health associ-
ated with oat consumption, ranging from reduction in risk of
cardiovascular diseases2–4 to cancer prevention.5,6 Compared
with other cereals, oats have higher concentrations of certain
nutrients and phytochemicals (e.g., essential amino acids and
fatty acids, β-glucan and phenolic compounds), and they can
tolerate harsher growing conditions such as wet climate and
acidic soil, making them more resilient than other crops.7
In the ageing population of Western countries, cardio-
vascular disease (CVD) and related conditions are a huge
public health burden. According to the World Health
Organisation (WHO), CVD is the number one cause of death
globally. For example, in 2015, 17.7 million people died
from CVD. Elevated serum cholesterol (hypercholesterolaemia)
is a significant risk factor for developing CVD.
Hypercholesterolaemia can be treated by prescribing statins
but this therapy is associated with various negative side-
eﬀects. Diet is a key risk factor for the development and pre-
vention of CVD.8 Thus, using dietary approaches that tackle
risk factors such as increased serum cholesterol levels and
high systolic blood pressure should be a key strategy for the
prevention of CVD and other metabolic disorders.
The first study to reveal that oat consumption reduced
plasma cholesterol levels goes back to 1963.9 By enriching
bread with rolled oat, the authors observed an 11% reduction
in total cholesterol levels. Since then a multitude of in vivo and
in vitro investigations have been conducted to understand the
reasons behind this positive eﬀect.2–4,10–15 To date, the chole-
sterol-lowering eﬀect of oat has been attributed primarily to
the β-glucan it contains.2,3,10,13,14 Although the precise mecha-
nisms involved are not completely understood, the ability of
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β-glucan to lower cholesterol is thought to be triggered by
several processes.11,16 Firstly, the presence of β-glucan in the
small intestine may increase the viscosity of intestinal con-
tents, which could delay gastric emptying, reduce intestinal
mixing, entrap mixed micelles, and restrict the mixing and
transport of nutrients, digestive enzymes and bile salts.17
Secondly, it has been hypothesised that β-glucan could also
interfere with the enterohepatic recycling of bile salts by direct
interaction.11 However, the eﬀect of β-glucan on bile salt
metabolism still remains unclear as recently demonstrated by
the same authors.18,19 Finally, β-glucan has been shown to
interact with the mucus layer resulting in a diminution in the
porosity of the intestinal mucus and thereby a reduction in
nutrient absorption.20
Following a review of some of the human studies on the
subject, health claims were approved in the United States in
1997 by the Food and Drug Administration (FDA),21 and later
in Europe by the European Food Safety Authority (EFSA)22 and
in Canada. These claims stipulated that foods should provide
at least 3 g per day of β-glucans in order to obtain the claimed
eﬀect. The EFSA regulation stipulates that oats should be con-
sumed in a minimally processed form. Indeed, not all food
products containing β-glucan seem to lead to the same health
outcome; overall processes that degrade β-glucan result in pro-
ducts that are less eﬀective at reducing plasma cholesterol.23
Current knowledge suggests that the complexity and struc-
ture of the matrix or interactions between diﬀerent com-
ponents are key factors controlling functionality.24–27 Thus far,
few studies have fully characterised the physicochemical pro-
perties of oat or oat derived ingredients (e.g., detailed chemical
analysis of nutrients, integrity of cell walls, rheology, location
and physical state of starch granules, protein bodies and oil
bodies, and β-glucan molecular weight and content), making
interpretation of these findings diﬃcult. In addition, conflict-
ing findings might be notably the consequence of a reduction-
ist, nutrient-focused (i.e., β-glucan) approach.28,29
This review will focus on the influence of the structure and
complexity of the matrix of oat and oat-based foods on their
nutritional impact in order to provide information for future
research on the mechanisms influencing the beneficial health
attributes of oat.
2. The oat matrix and its impact on
cholesterol and risk of cardiovascular
disease
2.1 Oat structure and composition
A food matrix can be described as the structure and hierarchi-
cal organisation (from molecule to tissue) of the components
of a food product.26 The spatial arrangement and the relation-
ship between the components constitutive of the plant food
matrix can occur naturally (e.g., cellular structure of plant
tissues) or result from processing (e.g., network structure
developed during breadmaking). The oat grain is a complex
matrix containing the protective hull and the groat (caryopsis),
the latter being composed of the bran, germ and starchy endo-
sperm (Fig. 1).30 The bran is a coarse outer layer rich in min-
erals, vitamins, and cell wall polysaccharides, mainly cellulose,
arabinoxylan and β-glucan. Below the pericarp and seed coat
of the bran, there are the aleurone and subaleurone layers
joined to the endosperm. The aleurone and subaleurone cells
are surrounded by thick cell walls resistant to digestion,
whereas the endosperm cells have thinner cell walls, rich in
β-glucan. The oat protein and lipid increase in concentration
from the interior to the periphery of the groat, while starch
increases from the subaleurone region to the centre of the
Fig. 1 Structural representation of the oat grain presenting diﬀerent oat tissues (i.e., the bran, germ and endosperm) and the nutrient distribution/
organisation within these tissues.
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endosperm.30 The structure and composition of the proteins
(globulins, albumins, prolamins (avenin) and glutelins) diﬀer
depending on the part of the grain in which they are located.31
Two types of starch granules exist in the endosperm: com-
pound and single granules.30 The proportions of amylose and
amylopectin, and the size of the granules vary between oat
varieties.
Oat is potentially a good source of macronutrients, vita-
mins, minerals, and other phytochemicals, but the actual
dietary intake depends on the part of the grain (i.e., endo-
sperm vs. bran) that is consumed and how it has been pro-
cessed.32,33 The proportion of the diﬀerent nutrients can also
be altered.34 One common practice employed by manufac-
turers to increase the β-glucan content of oat products is to
add high β-glucan content grain fractions.
Fig. 2 summarises the diﬀerent levels of oat structural com-
plexity, from the plant to the purified β-glucan, including oat
products commonly consumed. The oat ingredients frequently
found in the literature are bran, purified β-glucan, flakes (also
called oatmeal or rolled oats) and flour. Rolled oats exist in a
wide range of particle sizes (from ∼0.2 to a few mm; e.g., large
flake, Irish steel cut, Scottish, quick and instant oat
flakes).35,36 Oat bran is produced by grinding and sieving to
remove part of the starch and is available in a range of particle
sizes. According to the definition from the American
Association for Cereal Chemistry, oat bran must contain a
minimum of 5.5% β-glucan34,37 but fractions are available with
β-glucan contents up to 40%.35,36 They can then be incorpor-
ated into other food products, such as breakfast cereals (i.e.,
ready-to-eat cereals, muesli, and granola), biscuits and
cookies, cereal bars, bread, and muﬃns.36
Oat extracts are made by extracting the β-glucan using
enzymatic and/or solubilisation methods. Several extraction
methods have been patented including those that use
amylases,38–40 freeze/thaw fractionation,41 and solubilisation
with basic solutions.42 These purification methods can achieve
much higher β-glucan concentrations than dry milling
methods. For more details of the protocols and advantages/
disadvantages of each method, the readers are referred to
earlier articles.12,43
2.2 Oats and their cholesterol-lowering eﬀect
In this review, we chose to investigate the eﬀect of oat and oat-
based products on lipemia (cholesterol and triglycerides) and
other cardiovascular risk factors based on the diﬀerences in
food matrices in order to correlate diﬀerential eﬀects accord-
ing to the physicochemical characteristics of these matrices. It
has been established that subjects with mildly elevated chole-
sterol levels have to consume at least 3 g of β-glucan per day to
observe a significant reduction in their serum total- and low-
density lipoprotein- (LDL) cholesterol levels.3 A study that com-
pared the eﬃcacy of extruded oat bran cereals, which under-
went graded increases in the temperature and pressure used in
the extrusion process to modify the β-glucan so that they had a
range of molecular weights, indicated that the increased vis-
cosity in the gastrointestinal tract played a role in the mecha-
nism of action.44 The increase in viscosity prevents eﬃcient
mixing of the luminal contents, which results in decreased
Fig. 2 Diagram showing the structural levels of oat, from the plant to extracted β-glucan, and some oat forms commonly consumed (i.e., steel cut
oat grain, oat ﬂakes, oat ﬂour, oat bran and puriﬁed β-glucan).
Review Food & Function
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intestinal uptake of dietary cholesterol and decreased re-
absorption of bile acids.45 β-Glucan can interfere with the
enterohepatic circulation at diﬀerent levels including limiting
the return of bile acids to the liver, which triggers an increase
in hepatic conversion of cholesterol into bile acids and thereby
a decrease in blood cholesterol levels.46
Numerous oat products have been used as a source of
β-glucan, in both in vitro and in vivo studies. The most studied
products or ingredients are purified β-glucan, oat bran, oat
flakes and oat-based food products. The latter were made of
oat that underwent various degree of processing, and may have
contained part of the oat tissue (e.g., bran, flour and flakes) or
only certain oat constituents (e.g., β-glucan). Table 1 presents a
summary of the human studies mentioned in sections 2.2.1 to
2.2.4 based on product type.
2.2.1. Purified β-glucan. A few studies have investigated the
cholesterol lowering potency of purified forms of β-glucan.
Several methods exist to extract the polymer from the oat
tissue with consequences on its molecular weight and
content.12 It is actually challenging to obtain pure β-glucan
extracts of both high concentration and molecular weight.
Purified oat extracts were originally called oat gums.47 Gums
can be described as water-soluble fractions of plant, fungal,
animal or synthetic origin, rich in a particular polysaccharide.
Consumption of 2.9 g per day of oat extract by mildly
hypercholesterolemic humans resulted in a 9% decrease in
LDL cholesterol levels compared to the placebo (maltodextrin)
phase of the trial.48 Interestingly, when oat extract was discon-
tinued, total and LDL cholesterol returned to initial levels in
one study with hypercholesterolemic male and female adults.
In rats fed an oat extract, cholesterol uptake by everted jejunal
sacs was progressively inhibited by increasing the concen-
trations of oat gum in the mucosal medium.49 Other studies
have shown that oat extracts can reduce cholesterol and LDL
cholesterol oxidation in vitro. This oxidation is thought to be
involved in the first steps of atherosclerosis.50,51 Cholesterol
oxidation in vitro was also inhibited in a dose-dependent
manner upon the addition of oat extracts.52 These antioxidant
eﬀects are thought to be due to the phenolic compounds
present in the oat extracts.
In rats, the eﬀect of native β-glucan as well as β-glucan
hydrolysates (product of acidic or enzymatic β-glucan hydro-
lysis resulting in polysaccharides of smaller molecular weight)
on cholesterol and lipid metabolism was investigated.53,54
Both supplements significantly reduced the levels of LDL and
very low-density lipoprotein (VLDL) cholesterol in serum and
further improved the lipid profile in liver.53 Greater serum tri-
glyceride reduction was observed with β-glucan hydrolysate of
an average molecular weight of 730 kDa (vs. native) but total
cholesterol reduction was insignificant with both β-glucans. In
addition, the hydrolysate was more eﬀective at increasing the
excretion of faecal cholesterol and triglyceride than the native
β-glucan, showing its eﬀectiveness in improving the lipid
profile. In contrast, in mice fed a high-fat diet supplemented
with β-glucan of three diﬀerent molecular weights obtained
through enzymatic hydrolysis (1450, 730, and 370 kDa), signifi-
cant reductions in LDL cholesterol resulted, with no eﬀect of
molecular weight on the serum lipid profile.54 The main limit-
ation of these studies was the extremely large amount of
β-glucan given to the rodents (∼8.5 g of β-glucan per day),
which is far in excess of any published human study (account-
ing for body weight and meal size). The large doses adminis-
tered would result in high viscosity, even for low molecular
weight samples, which could also have interfered with the
digestibility of the matrix and thereby serum lipid and chole-
sterol levels. Therefore, caution must be taken in extrapolating
these results to humans.
In hypercholesterolemic rats fed diets containing oxidized
β-glucan, the levels of triglyceride, total cholesterol, LDL chole-
sterol, and VLDL cholesterol significantly decreased and more
faecal elimination of total cholesterol and triglyceride was
observed – in correlation with their reduced levels in serum
and liver.55 The authors also showed that oxidation of the
β-glucan increased its bile acid sequestration (“binding”) capa-
bility. Although this eﬀect was relatively small, this interaction
between the oat matrix and the bile acids could contribute to
the observed increase in fat and cholesterol excretion. In
addition, the oxidation significantly increased the water solu-
bility of β-glucan by modifying the polarity of the polymer.
This would result in a higher water holding capacity and
increased viscosity, which could also support the hypothesis
linking luminal viscosity with reduced lipid digestion and
uptake, leading to reduced serum cholesterol levels as
described earlier in section 2.2.
Beverages enriched with 5 g of oat β-glucan (molecular
weight of 70 kDa)56 decreased the levels of total plasma chole-
sterol in hyperlipidemic subjects. However, the reductions in
LDL cholesterol were not significant compared to controls
(where the LDL cholesterol unaccountably increased during
the study, which is a major issue) but were significantly lower
than baseline measurements. Interestingly, larger amounts of
β-glucan did not necessarily lead to a higher impact on
lipemia since the beverage with 10 g of β-glucan from oat did
not aﬀect serum lipids significantly in comparison with a
control with no added β-glucan.
Overall, purified β-glucan administered under diﬀerent
forms can lead to a small decrease in cholesterol levels, but
the results appear inconsistent between studies, which may be
due to the treatment applied to the β-glucan.
2.2.2. Oat bran. Oat bran as such has been tested in
animal models and in humans. In the most recent study per-
formed on mice, all oat bran preparations significantly
reduced plasma cholesterol when compared with a cellulose-
containing control diet, regardless of the molecular weight
of β-glucan (2348, 1311, 241, 56, 21 or <10 kDa).57 In this
study, the diﬀerence in viscosity between the processed oat
brans did not appear to play a major role in the cholesterol-
lowering properties. However, the dose given to the mice
was 6.8–8.4% β-glucan so that even the diets containing low
molecular weight β-glucan were capable, according to the
authors, of generating a significant increase in viscosity in
the gut.
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Table 1 A summary of some of the human studies on the eﬀect of oat-based products on lipemia
Ref. Process Oat-based products Dose (per day) Texture
TC
(%)
LDL-C
(%)
TAG
(%)
Bremer (1991)85 Fermentation
Baking
Oat bran bread 44.6 g of oat bran Solid NS NS NS
Frank (2004)86 Yeast-leavened oat bran breads
containing BG of low or high average
molecular weight
6 g of BG Solid NS NS nd
Kerckhoﬀs (2003)87 Oat bran bread 5.9 g of BG Solid NS NS nd
Liatis (2009)81 Oat flour bread 3 g of BG Solid −13 −16 −12
Reyna-Villasmil
(2007)79
Oat bran bread 6 g of BG Solid −16 −28 NS
Zhang (1992)80 Oat bran bread 118 g of oat bran,
29 g of DF
Solid −11 −15 nd
Anderson (1990)88 Breakfast cereals Oat bran cereals (flakes, biscuits or
ready-to-eat cereals)
25 g of oat bran,
8.8 g of DF
Solid −5 −9 nd
Bartram (1992)77 Oat bran cereal muesli 60 g of oat bran Solid −11 −11 nd
Beck (2010)68 Oat cereals (ready-to-eat cereals or
flakes, and muesli bars)
5–6 or 8–9 g of BG Solid and semi-
solid
NS NS NS
Bindu (2013)89 Oat flakes 35 g of oat Semi-solid NS −8 NS
Charlton (2012)63 Oat cereals (ready-to-eat cereals, flakes
and snack bars)
1.5 or 3 g of BG Solid NS −18 NS
Davy (2002)64 Oat flakes and ready-to-eat cereals 5.5 g of BG Solid and semi-
solid
NS NS NS
Gold (1991)78 Ready-to-eat oat bran cereals and snack
bars
38 g of oat bran Solid NS NS nd
Lovegrove (2000)90 Oat bran incorporated into ready-to-eat
cereals
3 g of BG Solid NS NS NS
Maki (2010)91 Whole-grain ready-to-eat oat cereals 3 g of BG Solid −9 −5 NS
Marlett (1994)92 Oat bran cereals 6.9 g of BG Solid — nd nd
Pins (2002)65 Oat flakes and ready-to-eat cereals 5.7 g of BG Solid −15 −16 nd
Thongoun (2013)69 Oat flakes 70 g of oat Semi-solid −5 −10 NS
Van Horn (1988)66 Oat flakes 56 g of oat Semi-solid −8 — —
Van Horn (1991)93 Oat flakes 56.7 g of oat, 5.6 g
DF
Semi-solid −6 −9 —
Van Horn (2001)67 Oat flakes 56 g of oat Semi-solid −5 −5 NS
Wolever (2010)23 Oat bran incorporated into ready-to-eat
cereals
3 or 4 g of BG Solid NS −6 NS
Zhang (2012)70 Oat flakes 100 g of oat Semi-solid −7 −9 NS
Amundsen (2003)94 Other products Premade diet containing oat bran
concentrate in 8 products (muesli,
extruded breakfast flakes, bread,
teacakes, muﬃns, tagliatelle pasta,
macaroni and an apple drink)
5 g of BG Solid and
liquid
−6 −9 nd
Chen (2006)95 Oat bran concentrate incorporated into
muﬃns and ready-to-eat cereals
7.3 g of BG Solid NS NS NS
Romero (1998)84 Cookies enriched with oat bran 2.6 g of BG Solid nd −26 NS
Stewart (1992)96 Oat bran 51.7 g of oat bran Solid NS NS NS
Swain (1990)97 Muﬃns and entrées enriched with oat
bran
100 g of oat bran Solid NS NS NS
Uusitupa (1997)61 Oat bran 10.3 g of BG Solid NS — —
Whyte (1992)62 Oat bran 123 g of oat bran Solid −3 −6 —
Beer (1995)98 Beverages Soups Oat gum instant whip 9 g of BG Semi-solid NS NS NS
Biorklund (2005)56 BG (70 kDa) incorporated into beverages 5 or 10 g of BG Liquid −7 −6 NS
Biörklund (2008)99 BG (80 kDa) incorporated into soup 4 g of BG Liquid NS NS NS
Cugnet-Anceau
(2010)100
BG (80 kDa) incorporated into soup 3.5 g of BG Liquid NS NS NS
Ibrugger (2013)101 BG (305 kDa) incorporated into
beverages
3.3 g of BG Liquid NS NS NS
Kerckhoﬀs (2003)87 Oat bran in orange juice 5.9 g of BG Liquid −4 −7 nd
Mårtensson
(2005)102
Fermented oat-based products 3 or 3.6 g of BG Liquid −6 −6 nd
Naumann (2006)103 BG incorporated into a fruit drink 5 g of BG Liquid −3 −5 NS
Onning (1998)104 Oat milk Liquid −4 −9 nd
Onning (1999)105 Oat milk 3.75 g of BG Liquid −6 −6 NS
nd: Not determined; NS: not significant; —: information not available. BG: β-Glucan; DF: dietary fibre; LDL-C: low-density lipoprotein; TAG:
triacylglycerol; TC: total cholesterol.
Review Food & Function
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In two studies performed in hamsters, total plasma chole-
sterol was significantly reduced (14% and 27%) by oat bran
(∼3 g of β-glucan) as compared with the cellulose control
diet.58,59 Then, Jackson et al. showed in rats that oat bran sig-
nificantly reduced the plasma cholesterol level and that in all
animals fed oat bran, the liver cholesterol level was lower than
in rats fed barley or malted barley.60 Studies in humans using
oat bran (Table 1) also reported plasma cholesterol reduction
but to a lesser extent (6%) than in animals. However, as indi-
cated above, the discrepancy might be due to the high dose of
oat bran administered to the rodents (about 3 g of β-glucan for
an animal weighing on average between 45 and 60 g, com-
pared with 3 to 10 g of β-glucan for a human presumably
weighing on average between 50 and 80 kg).61,62
2.2.3. Oat flakes. Diﬀerent diets (e.g., hypocalorific or rich
in various sources of oat β-glucan) that include oat flakes were
found to improve the plasma lipid levels of hypercholesterole-
mic subjects.63–68 Charlton et al. and Pins et al. reported the
largest decrease in LDL cholesterol: 18 and 16%, respect-
ively.63,65 However, these studies also included other, pro-
cessed foods such as snack bars and extruded cereals, so the
influence of these elements cannot be excluded. Other clinical
trials looking specifically at the impact of oat flakes on chole-
sterol also found a reduction in both total (about 6%) and LDL
(about 9%) cholesterol.69,70 In these investigations, the oats
were administered in a semi-solid form where flakes were
cooked with some liquid (milk or water).
2.2.4. Oat-containing foods. Oat-based products or
β-glucan enriched products have been generally tested in
humans or animals for their ability to reduce plasma chole-
sterol, in particular, LDL cholesterol levels.2,3,13 The other
cardiovascular risk factors studied in vivo were anti-athero-
genic potential,71 inhibition of cholesterol and fatty acid oxi-
dation,51 blood pressure,72–74 endothelial function,75 fibrino-
gen,76 and apolipoprotein.77,78
Oat may be incorporated into various matrices such as
fermented oat-based products (including breads), oat-based
breakfast cereals, pastries, beverages, oat-bran-enriched pro-
ducts and also in the form of oat extracts such as oat gum or
concentrates. We reviewed cholesterol and LDL cholesterol
reductions in humans according to these diﬀerent matrices.
There is no marked trend relating to matrices, whether they
are solid (e.g., oat bran bread), liquid (e.g., oat milk) or semi-
solid (e.g., oat porridge and oat gum instant whip) (Table 1).
Therefore we cannot really confirm the conclusion of Othman
et al. that reduction in cholesterol levels may be greater when
β-glucan has been added to a liquid compared to a solid food
matrix.13 This will depend on the solubilisation or dispersion
of β-glucan from the food matrix during either preparation,
processing or consumption and digestion (see sections 3.1 and
3.2).
As for solid, fermented oat-based products (e.g., bread),
their consumption in humans led to cholesterol reduction up
to 16% and LDL cholesterol reduction up to 28% but no eﬀect
on plasma triglycerides.79–81 The influence of β-glucan hydro-
lysis has been studied in ileostomy subjects consuming oat
bran bread with and without added β-glucanase.82 The bread
containing oat bran led to a 53% higher bile acid excretion
than oat-bran bread with β-glucanase, probably explaining the
eﬀect of oat fibre in lowering the levels of serum lipids.
However, the results can be inconsistent between studies, with
some of them showing no significant eﬀect (Table 1).
Concerning oat-based breakfast cereal, involving more
intensive technological processes than fermentation (e.g.,
extrusion), cholesterol reduction may reach 15% and LDL-
cholesterol reduction 16%, while no triglyceride reduction was
observed (Table 1). In the most recent study, oat cereal pro-
ducts providing either a total of 3 g high-molecular-weight
(2250 kDa), 4 g medium-molecular-weight (850 kDa), 3 g
medium-molecular-weight (530 kDa) or 4 g low-molecular-
weight (210 kDa) oat β-glucan were given for 4 weeks to
367 men and women aged 35 to 70 years with body mass index
≥18.5 and ≤40.0 kg m−2.44 The authors observed that, while
high-molecular weight and medium-molecular weight oat
cereal decreased LDL-cholesterol, low molecular weight had no
eﬀect. This decreased beneficial eﬀect with low molecular
weight β-glucan was confirmed by the same research team in a
similar study using an extruded cereal containing β-glucans.
Those with molecular weights of 2210 kDa and 530 kDa
lowered the LDL cholesterol, globulins, albumins, prolamins
(avenin) and glutelins by around 5%. The eﬃcacy was reduced
by 50% when the molecular weight was reduced to 210 kDa.23
In another study in hamsters, bran from oats was cooked in a
twin-screw extruder at either high or low energy input but in
this particular case, extrusion did not alter its hypocholestero-
lemic eﬀects.83
Concerning other processed foods there are only a small
number of studies showing no convincing or inconsistent
eﬀects on cholesterol reduction (Table 1). Apart from one
study that revealed 26% reduction of LDL-cholesterol by
cookies enriched with oat bran,84 in another clinical trial,
plasma cholesterolemia was not measured but cholesterol
absorption was evaluated isotopically in six ileostomy subjects
following test meals composed of thick pancakes made pri-
marily from commercially available oat bran or wheat flour
and served with crème fraiche and apple sauce.45 The results
showed that the postprandial cholesterol concentration in the
chylomicrons was reduced by 43% after the oat bran test meal
was consumed, indicating a decrease in the amount of chole-
sterol that gets transported from the intestine to other tissues
in the body, whereas there was no diﬀerence in cholesterol
absorption. The excretion of bile acids and lipids was also
increased after consumption of oat bran compared with the
control meal. In addition to the well-known hypothesis of
viscous β-glucan promoting bile acid excretion (i.e., entrap-
ment of bile acids within the viscous intestinal content) and
subsequent changes in the synthesis and endogenous
excretion of cholesterol (i.e., increased conversion of chole-
sterol into bile acids to compensate for the loss), the authors
hypothesized a delay in the micellar lipid solubilisation
process and a consequent reduction in the secretion of chylo-
microns into the circulation. It is clear that processing of the
Food & Function Review
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oat itself, or the delivery vehicle, has the potential to signifi-
cantly aﬀect the properties and hence functionality of
β-glucan. However, in many of these papers, a detailed analysis
of the β-glucan component (e.g., purity, content and molecular
weight, and structural features such as the ratio of tri-
saccharide to tetrasaccharide units or the DP3/DP4 ratio) was
not performed. Thus, the inconsistency between the results
reported here is likely to be due to the variability in the oat
matrices studied and the subsequent impact on the physico-
chemical properties of β-glucan and other oat components.
Finally, the simplest type of vehicle in the form of bev-
erages (where nutrients are in contact with free water), such
as milk or fruit drinks into which oat products have been
incorporated, has been found, in general, to have a more
regular eﬀect on cholesterol reduction compared to more
complex matrices. Consumption of these beverages systemati-
cally led to cholesterol and LDL-cholesterol reductions in all
the studies reported (Table 1). However, the reductions never
exceeded 9%. Considering that these are the simplest
vehicles, there is less scope for physical interactions within
the matrix and for improving the conditions for β-glucan
hydration; therefore the physiological impact is possibly due
mainly to β-glucan alone, whereas for the more complex,
solid foods, interactions between β-glucan and the food
matrix, for either natural or processed foods, appear to either
negate or accentuate the eﬀect. This suggests that not only is
the processing of the oat β-glucan important, but the matrix
or vehicle in which it is delivered is also critical for its ability
to reduce serum cholesterol levels. Therefore, further
research is required to understand how the physicochemical
properties of the β-glucan influences its interactions with
other components and structures in minimally processed
(i.e., where the oat tissue remains mostly intact), solid food
matrices in order to fully understand the mechanisms of
action and maximise the health benefits of oats.
In the majority of human studies the physicochemical
or structural characteristics/properties of oat are not
reported.2,3,10,13,14,106 The variabilities due to cultivars,
environmental conditions, storage conditions and the proces-
sing technique applied to the oats are often ignored. The oat
variety and the maturity of the grain are likely to have a signifi-
cant eﬀect on the amount and properties of the β-glucan
present in the grain32,107 as well as on the starch, protein and
lipid content.1 The quantity of β-glucan contained in the oat
products given to the participants are, most of the time, esti-
mated, and the β-glucan molecular weight not systematically
measured.2,3 More importantly, the actual structure of the oat
tissue and the overall food matrix used to administer the bio-
active compounds (e.g. liquid vs. solid, water activity, organis-
ation within the matrix, and degree of disruption of plant
tissue) have rarely been considered.
In order to understand better the mechanisms involved, it
seems essential to, firstly, have some information regarding
the source and processing conditions of oats, and secondly, to
fully characterise the food product(s) studied, which should
include nutritional analysis but also, for example, the particle
size of the oat tissue, the presence and amount of gelatinised
starch, and the extent of oat cell degradation.
From the studies on the impact of oat and β-glucan-based
products on plasma cholesterol in humans, it is diﬃcult to
draw firm conclusions, notably related to the potential matrix
eﬀect. Increasing the degree of matrix complexity led to con-
flicting results concerning its impact on lipemia (Table 1).
However, the dose, study design, status (e.g., hypercholesterole-
mic and overweight) and genetic characteristics of the sub-
jects, food matrices, and molecular weight of β-glucans appear
to greatly diﬀer from study to study, making their comparison
hazardous. Therefore, three hypotheses may be advanced but
they require further investigation: (1) liquid oat-based foods
seem to give more consistent, but moderate reductions in
cholesterol than semi-solid or solid foods where results are
more variable; (2) the quantity of β-glucan and molecular
weight at the expected consumption levels (∼3 g per day) play a
role in cholesterol reduction; and (3) natural β-glucan-rich oat
based foods often appear to be more eﬃcient at lowering
cholesterol or lipemia than β-glucan added as an isolated
ingredient.
3. Degree of processing and
functionality
3.1 Eﬀect of processing on oat grain structure and
constituents
Despite being necessary for food safety, conservation, conven-
ience, palatability and digestibility, processing can generate
foods whose regular consumption has been associated with
the development of chronic lifestyle related diseases (i.e.,
obesity and cardiovascular disease)108–110 associated with a
“Westernised diet”.111 This can be attributed to several
reasons, including recent concern about the role of processing
in food health potential and the very late recognition of the
food matrix eﬀect in defining its health potential,28 especially
for cereal-based foods.112 These eﬀects are usually (but not
exclusively) linked to the ability of the food matrix structure to
control the rate and extent of breakdown, digestion and
release of nutrients.113 The eﬀects can be direct, by increasing
gastric volume and reducing gastric emptying, thus promoting
satiation and prolonging appetite.114 Conversely, they can be
indirect, by restricting nutrient bioaccessibility,115–117 thus
delaying nutrient uptake, and hence reducing glycaemic and
lipidemic responses. This can have positive benefits by pro-
moting satiety and improving insulin response. Today we
know that the populations adhering the most to highly pro-
cessed foods, which are more easily digested, are the most
prone to develop non-communicable diet-related chronic
diseases.118–124 In reality, processing impacts both the food
structure and composition,125 and this has to be taken into
consideration for oat-based foods. The matrix eﬀect for these
foods includes physicochemical characteristics of the matrix
such as nutrient interaction, matrix structure (i.e., solid vs.
semi-solid vs. liquid), degree of β-glucan polymerization and/
Review Food & Function
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or intensity of processing applied. For example, a recent study
showed of 378 ready-to-eat foods that the more a food is pro-
cessed, the less satiating and the more hyperglycaemic it is,
with matrix eﬀects (i.e., impact of overall food structure and
physico-chemical properties) playing an essential role in both
outcomes.126,127 However, for oat-based foods, we are con-
fronted with a paradoxical eﬀect since the more products are
unstructured, the more β-glucans seem available to exert a
cholesterol lowering eﬀect, but at the same time, an unstruc-
tured food (for example, when cell walls are ruptured) is likely
to increase starch and glucose bioaccessibility, thus increasing
glycaemia. So, it remains unresolved whether cholesterol low-
ering, increased satiety and decreased glycemia can be
achieved in the same food.
Oat grains have to undergo some form of processing before
their nutrients become digestible.35 Overall technological treat-
ments may be classified into the following main groups:
mechanical, thermal, enzymatic and chemical treatments as
well as refining (or fractionation/recombination) and fermenta-
tion. In emerging and developing countries, malting, pre-
soaking and pre-germination are also often used in traditional
foods. First, the grain has to go through cleaning, grading and
dehulling. The bran and germ remain on the groat after the
dehulling process because the aleurone layer does not separate
from the endosperm as easily in oat as it does in other cereals
such as wheat.30 Consequently, the dehulled oat groat retains
a concentrated amount of dietary fibres (e.g., β-glucan) and
other phytochemicals (e.g., vitamins, minerals, and phenolic
compounds). Naked oats, a hull free variety, have a diﬀerent
nutritional profile compared to dehulled oats. In general, the
former contains a smaller amount of fibres but larger amounts
of proteins, lipids and certain phenolic compounds than the
latter.128,129 The absence of hull presents the advantage of
reducing the cost for the food processing industry.130,131
During kilning, a steaming process takes place as a part of oat
milling. Here, Maillard reactions occur that improve the taste
of the product while promoting stability of lipid and anti-
oxidant compounds by deactivating endogenous enzymes.35
Oat flakes remain the most common way to eat oat.36
Flakes are obtained by flattening whole or steel-cut groats.
They are often partially precooked to reduce cooking time and
then dehydrated.35 Flour can be produced by grinding the
whole oat groat or flakes with a pin or hammer mill. β-Glucan
is found in the cell walls, especially around the aleurone layer
and outer endosperm (Fig. 1). Coarsely ground flour can then
be sieved or air-classified to produce bran with an increase in
the β-glucan content.
The release rate and extent, solubility and molecular weight
of β-glucan when in a food product have been shown to be
aﬀected by cooking and freezing, in particular, repeated
freeze–thaw cycles.132–135 It is essential to consider the storage
conditions and pre-treatment (e.g., hydrothermal and/or
ethanol) applied to the oats, notably to prevent degradation
from endogenous enzymes. The size of the oat particles and
the nature of the food matrix in which they are incorporated
have also been revealed to have, in in vitro studies, a signifi-
cant impact on the rate and extent of β-glucan release.136,137
When milled oat bran was included in individual food
matrices made of protein (egg white), starch (potato starch) or
lipid (butter oil), protein and starch matrices led to only 5% of
β-glucan release at the end of in vitro gastric digestion com-
pared with ∼50% for the particles without the matrix.136
Hydrothermal processing generally increases β-glucan extracta-
bility;138 however, our recent study showed a reduced release
of the polymer.137 This is possibly due to the cooking method
used in the latter study (i.e., water and oats were mixed
together and then gradually brought to the boil) that promotes
swelling of the cell wall and gelatinisation of the starch, hence
restricting access of water to the β-glucan.137 Fermentation has
also been found to increase the solubility of β-glucan.139
The methods used to extract β-glucan from oat (e.g., pH,
temperature, liquid to solid ratio, wet vs. dry milling, the par-
ticle size, enzyme treatment and the oat source) have conse-
quences on the physicochemical properties of the polymer.12
The extraction process determines the yield and degree of
purity of the β-glucan extract, but also its rheological behaviour
since the latter is controlled by the β-glucan molecular weight,
solubility, conformation and concentration.140,141 Similar to
the case when it is incorporated into an oat-based product,
extracted β-glucan can be depolymerised due to the storage
conditions or the extraction process itself.15 The solubilisation
of high molecular weight β-glucan can be diﬃcult to achieve,
in particular if the preparation has been freeze-dried
beforehand.142
Germination/malting stimulates the expression of cell wall
degrading enzymes,143 such as xylanases and glucanases, to
break down the endosperm cell walls and allow access to the
starch as an energy source to support germination and growth.
The enzyme action will solubilise β-glucan from the cell walls
and make it more available, but also the molecular weight may
well be reduced.
Extrusion is a highly intensive process, simultaneously
applying high pressure, shear and temperature to create food
products with a range of structures and textures. Extrusion will
degrade and reorganise the oat matrix into a more homo-
geneous structure.144 This may result in protein denaturation
and aggregation, solubilisation and degradation of cell wall
polysaccharides and the partial destruction of amylose–lipid
complexes. These changes in structure and interactions are
likely to aﬀect the food digestibility and the subsequent
physiological responses (e.g., lipaemia, cholesterolaemia and
glycaemia). However, these eﬀects are highly dependent on
processing conditions. Brahma et al. showed that under their
conditions they could increase the amounts of resistant starch
and water-extractable β-glucan by decreasing the water content
during the oat extrusion, without aﬀecting the β-glucan mole-
cular weight.145 However, Tosh et al. also showed that drastic
extrusion conditions caused β-glucan depolymerisation, loss of
cell wall integrity and β-glucan dispersion throughout the
cereal.146 In addition, alongside molecular weight reduction,
diﬀerences in the hardness and density of the extruded cereals
became more obvious.
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Thermal treatment applied to the grain can influence the
amount of soluble proteins present in oat flour and the
binding sites of globular proteins responsible for binding poly-
saccharides.147,148 The properties of the starch granules such
as their size, swelling capacity, and rheological behaviour are
also altered during processing.148,149 Therefore, the processing
induced changes occurring to the overall structure of the oat
and the macronutrients it contains will aﬀect the release and
solubilisation of β-glucan and subsequently its eﬀect on lipid
and cholesterol metabolism.33,137,138,150
3.2 Eﬀect of processing on oat functionality
As we had previously underlined, processing can influence the
oat matrix (qualitative eﬀect) and its composition (quantitative
eﬀect). As we will discuss in the next section, we are con-
fronted with a double complexity: firstly, a single compound
(i.e., β-glucan) may have eﬀects on several physiological func-
tions, and secondly, several oat compounds may impact one
defined physiological mechanism such as cholesterol
reduction (see section 4).151 Processing, by disrupting the food
matrix, facilitates the digestibility and bioavailability of nutri-
ents but can also degrade the functionality of a food by alter-
ing the structure of its components (e.g., depolymerisation of
β-glucan, lipid coalescence and protein denaturation) and/or
the interaction between them.
As discussed above, purified forms of β-glucan were found
to be less successful at inducing changes in blood
lipids56,86,98,99,101 than intact oat tissues.23,152 This is consist-
ent with epidemiology studies showing that whole grain
intake, but not fibre alone, is inversely associated with athero-
sclerotic progression and cardiovascular disease.153,154 The
functionality of oats on cholesterolemia has been ascribed to
the capacity of β-glucan to increase the viscosity of the intesti-
nal content. Products containing both the bran and the endo-
sperm of the oat (i.e., oat flakes or flour) are likely to exhibit a
complex rheological behaviour due to the presence of β-glucan
but also proteins and starch.137,149 The rate and extent at
which these nutrients are released from the food matrix and
solubilised in the gastrointestinal tract will have consequences
on the viscosity of the digesta and thereby their physiological
activity.15 Very few studies measured the water activity of oats
or oat products; however, water that is freely available within
an oat product will dictate the solubility of the β-glucan and
the interactions between oat constituents.155,156 The associ-
ations between water and other molecules is also specific to
the product. The diﬀerence in water activity could be one of
the reasons why diﬀerences were observed in the cholesterol
lowering properties of various oat products. This is likely to be
due to the competition for available water between the starch,
β-glucan, and other water soluble polymers in the matrix. This
will be strongly aﬀected by processing. For example, the eﬀect
of hydrothermal processing will depend on the quantity of
water present as the amount of starch gelatinisation will lead
to a huge demand for water within the product, and thus
aﬀect the amount of soluble β-glucan that will be made
available.
The main modification occurring to β-glucan during the
processing of oat and oat-based products is depolymerisation.
β-Glucan depolymerisation occurs if the β-glucanases present
in the oat grains are not inactivated.47 Although kilning of oats
is used to inactivate lipases that makes the oats rancid over
time, it has the added benefit of reducing the activity of
endogenous β-glucanases as well.35 A reduction in β-glucan
molecular weight has also been observed during the pro-
duction of bakery products as shown with oat breads contain-
ing wheat flour.157 The β-glucanases naturally present in wheat
flour degrade the β-glucan during the fermentation process.158
The general assumption behind the cholesterol-lowering eﬀect
of oat and the β-glucan it contains is that higher β-glucan
molecular weight may contribute to higher viscosity in the gas-
trointestinal tract and subsequently to greater plasma chole-
sterol reduction. Kim et al.159 suggested that the “molecular
weight of β-glucan should be at least 1200 kDa in order to
elicit a cholesterol-lowering impact”.13 Wolever et al. (2010)
showed that extruded cereals with average molecular weights
of 530 kDa were eﬀective at doses of 3 g of β-glucan per day.23
However, the viscosity of the intestinal content relies not only
on the molecular weight of the β-glucan, but also on its con-
centration, structure and behaviour in solution.15,146,160
Indeed, the polymer has to be present in a certain size range,
at a given concentration, and dissolved in solution to form an
entangled network, which then will result in an increase in vis-
cosity. This is a complicated process that has been well
described elsewhere.161,162
The inconsistency in the outcomes from human studies
implies that the mechanisms are much more complex than
originally thought. These findings reinforce the importance of
considering the whole matrix for the delivery of bioactives.
Similar eﬀects have been found for phytochemicals other than
β-glucan, where the consumption of whole fruits and veg-
etables seems to have a more beneficial eﬀect than purified
phytochemicals, such that the structure and delivery form are
as important for functionality as the bioactive itself.163
4. Synergistic action of
oat constituents
In their article published in 2009, Jacobs and co-workers
clearly presented the concept of food synergy24 and later, in
2014, Fardet and co-workers showed the necessity for nutrition
research to move towards a holistic, integrative approach.164
Food synergy means that the action of some nutrients and
phytochemicals within a whole, natural food matrix is greater
than the corresponding action of the same food constituents
taken individually. In other words, synergy reflects that 2 > 1 +
1.24,29,164 Therefore, the quantity of a bioactive may become
irrelevant if the quality of the delivering system (i.e., food
matrix) is ignored. A coordination exists between food com-
ponents that may be lost during extensive processing; pairing/
interaction is likely to be fundamental for the functionality of
bioactives. More recently, the same authors discussed the
Review Food & Function
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arrangement of molecules within a food and showed how it is
fundamental for biological functionality of the raw material.29
For example, β-glucans are associated with the cell walls in the
outer layers of the endosperm and are thought to be involved
in protection against heat or drought stress.165 Therefore their
properties and location in the tissue during hydration and pro-
cessing could be critical to their health impact during diges-
tion. That arrangement of molecules that influences their
digestibility will have physiological consequences. By applying
these notions to oats and their impact on health, the following
questions arise: (i) What are the compounds present in oat
that exert a cholesterol lowering eﬀect? (ii) Is the combination
of these compounds enhancing their individual action? (iii) Is
their organisation within the oat matrix of significance for
their action?
Several compounds in oat may participate in improving
lipemia, especially cholesterolemia. Thus, the potential oat
lipid-lowering package includes β-glucan, arabinoxylans, poly-
phenols, phytic acid, phytosterols, policosanol, betaine,
choline, inositols, tocopherols and resistant starch.166–169
Besides the lipid-lowering package, a group of bioactive com-
pounds with other benefits to health may be found in oat-
based products, such as antioxidants, anticarcinogenic and/or
anti-inflammatory compounds.
4.1 Oat cholesterol-reducing agents
Oat groat is rich in a wide range of bioactive compounds,
some of them present in small quantities.43,167,169 These bio-
actives may act in combination in the gastrointestinal tract,
perhaps even synergistically, thus compensating for their
minor contribution. Apart from β-glucan, phytosterols, pheno-
lic compounds (e.g., avenanthramides), tocols and saponins
are other oat constituents that might have a direct or indirect
impact on cholesterol.43,168,170
The beneficial impact of phytosterols on plasma cholesterol
concentrations is now well documented.171,172 Phytosterols
and cholesterol are structurally and functionally similar but
diﬀer in the amount they are absorbed, which is thought to
contribute to reduced blood cholesterol. Some of the hypoth-
eses regarding the mechanisms of action include displacement
of cholesterol by phytosterols from the mixed micelles and for-
mation of mixed crystals leading to the precipitation and
excretion of cholesterol.173 Oat contains between ∼350 and
600 μg g−1 of phytosterols,43,168,170,174 mainly as β-sitosterol. A
portion of oat (30 g) will provide on average 40 mg of phyto-
sterols, which is much lower than the recommended ∼2 g
daily intake. However, despite the low concentration found in
plant foods, cholesterol reduction can be achieved following
the consumption of phytosterols from natural sources, in par-
ticular when consuming whole grain products.175
Twenty-four phenolic compounds exhibiting antioxidant
activity have been identified in oats.36,168,176,177 Their total
concentration ranges between ∼200 and 870 μg g−1, with phe-
nolic acids being the most common type. Phenolic compounds
exist in oat either as free, soluble conjugated or insoluble
bound to cell wall constituents. The form and the partitioning
behaviour of these compounds influence their bioavailability
and thereby their health eﬀect.26 The phenolic compounds
that are covalently bound to cell wall components (i.e., arabi-
noxylan) have a low bioaccessibility compared with the free
form.178,179 Avenanthramides, unique to oat, have been shown
to prevent LDL oxidation; increased levels of oxidised LDL may
contribute to atherosclerosis and cardiovascular disease.180,181
The majority of avenanthramides are found in oat bran
(∼20–90 μg g−1).43,168,177 To a lesser extent, caﬀeic and ferulic
acid also have antioxidant activity.176 When administered in
combination, these phenolic acids have been shown to have a
beneficial impact on the hypercholesterolemia of mice.182
Avenanthramides may also contribute to vascular smooth
muscle cell proliferation and cell cycle progression and nitric
oxide production.183,184
Tocotrienol concentrations in oat range from ∼16 to 36
μg g−1, primarily as α-tocotrienols (57 to 69%).168 In addition
to their antioxidant properties, the ability of tocotrienols to
reduce serum total cholesterol and LDL cholesterol levels has
been demonstrated in both animals and humans.185
Tocotrienols seem to aﬀect cholesterolemia by directly inhibit-
ing cholesterol synthesis.
Saponins are amphipathic glycosides that protect plants
from microbial and fungal infections.186 Avenacoside A and
avenacoside B are two saponins only found in oats.187 The
content of avenacoside decreases with the level of processing:
oat bran and flakes being richer than ready-to-eat cereals con-
taining processed oat products. Animal studies have revealed
that saponins could interfere with cholesterol metabolism,
albeit sometimes minimally.188–190 Saponins are thought to
exert their cholesterol-lowering eﬀect by forming a complex
with sterols that is not absorbed by the enterocytes, thereby
increasing the amount of cholesterol excretion.
For health benefits the active bioavailable dose appears to
be an important parameter to consider rather than the dose
ingested. It is essential to have a deep understanding of the
physicochemical properties of these compounds so that their
behaviour in the gastrointestinal tract during digestion can be
predicted. Furthermore, their interaction(s) with other nutri-
ents within and outside the food matrix is likely to promote
their bioavailability and/or eﬃcacy.
4.2 Food matrix eﬀect and synergy
As discussed in section 3, the degree of complexity of the food
matrix and its structural organisation can have an impact on
health by acting on two levels, the macro- and micro-scales.
On the macroscale, the structure of the food will aﬀect how
nutrients and bioactives are released, thereby influencing the
rate and extent of their digestibility. Firstly, a reduced rate of
nutrient digestion is likely to have health benefits related to
gastric emptying, satiety, glucose and lipid metabolism.115,117
Consumption of a complex, slowly digestible food matrix
would lead to a gradual release of nutrients, which will gene-
rate a moderate, controlled physiological response, for
example, reduced post-prandial lipidemia and/or glyce-
mia.117,191,192 Structurally complex foods may be better
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handled by the human body than over-processed (“pre-
digested”) ones. This is because over-processed foods are often
highly digestible, causing an overload of physiological cues eli-
cited by a rapid and large release of nutrients.127 This nutri-
tional overstimulation, when repeated through recurrent con-
sumption of highly processed foods, can lead to biological
malfunctions and diseases (e.g., dysregulation of appetite/
satiety and insulin resistance). Secondly, the reduced rate of
digestion will also permit a sustained release of bioactives as
observed with antioxidants.193,194 Thirdly, these bioactives
could be lost during processing.195
These phenomena also have consequences on the micro-
scale, where the food matrix will impact the functionality of
specific compounds by modulating their bioavailability, how
they are mixed and “circulated” in the gastrointestinal tract,
and their absorption, or not, into the enterocytes.196 The food
matrix could also modulate the interactions between diﬀerent
food compounds, which in turn could determine their delivery
to the site of action (e.g., lipophilic compounds requiring
lipids for their transport and uptake).197 The molecular inter-
actions and formation of complexes may either be essential for
or detrimental to the functionality of bioactives.193,194 As a
result, smaller amounts of bioactives, if they are delivered in
the most eﬀective form and/or in combination with appropri-
ate compounds, could potentially have a greater eﬀect than
larger amounts of individual molecules.198
As for evidence specific to oats, animal studies support the
concept of synergistic action of its components on lipemia,
particularly macronutrients and β-glucan.199,200 Guo et al.
found that five oat varieties, containing similar amounts of
β-glucan and phytosterols but varying in their protein and
lipid content, elicited a decrease in plasma cholesterol to
diﬀerent extents.199 The oat variety with the highest proteins
and lipids content produced the greatest cholesterol reduction.
The capacity of oats to sequester bile acids has been found
to be higher, presumably resulting in greater bile acid
excretion for complex sources of the polymer (i.e., oat flour),
than purified fractions.201 The authors concluded that several
components of the oat flour acted in synergy to elicit its hypo-
cholesterolemic eﬀect. Food matrices enriched with both
β-glucan and sterols from mushrooms (ergosterols) also
showed an enhanced displacement of cholesterols from
micelles compared with ergosterols on their own.202 Another
study performed on pigs revealed that the consumption of oat
β-glucan influenced the absorption of neutral sterols at
diﬀerent sites of the small intestine and in part of the colon.19
Because phytosterols have limited solubility both in water
and lipid, their bioavailability and eﬃcacy rely on many
factors, such as the quantity of lipid, the type of phytosterol
(i.e., sterol, stanol or ester such as steryl glycoside), the source
and the food microstructure.203,204 Similarly to β-glucan, the
eﬀect of phytosterols on blood cholesterol and cholesterol
metabolism depends on the food matrix (“vehicle” that deli-
vers the bioactives).205,206 Natural matrices, such as minimally
processed oat, may be an ideal form for the delivery of phytos-
terols. The mixture of free (i.e., sterol or stanol) and bound
(esters) phytosterols found in plant food,207 associated with
various nutrients, may facilitate their transport in the gastro-
intestinal tract and their delivery to their site of action.
Polyphenols when associated with dietary fibres have been
shown to reduce cholesterol levels.208 The material that sur-
vives gastrointestinal digestion and gets delivered to the colon
may promote the growth of bacteria having a positive eﬀect on
blood cholesterol concentrations, notably via bile salt hydro-
lase activity.209–211
It seems reasonable to venture the hypothesis that the pro-
portion of compounds present in oat, and the complex associ-
ations between them, influence the bioavailability and activity
of the bioactives. A thorough analysis of the literature on the
cholesterol-lowering eﬀect of oat, together with current knowl-
edge of the food structure, suggests that the concerted action
of the oat constituents, delivered in an optimal amount in
relation to each other, could enhance the functionality of oat
and elicit a positive, or balanced, physiological response.
Future work in this area should not focus solely on individual/
isolated nutrients that are removed from their “food context”,
but also incorporate detailed, well characterised studies of the
food matrix that contains the nutrients in order to shed some
light on the mechanisms behind the positive health eﬀects of
oat. Both in vitro and in vivo studies clearly demonstrated the
beneficial eﬀect of oat on cholesterolemia, which is unlikely to
be due exclusively to β-glucan, but rather to a combined and
synergetic action of several oat compounds acting together to
reduce blood cholesterol levels.
5. Conclusion
One of the main challenges faced today by the industry is to
find the right balance between none or little food processing
and high levels of food transformation. As discussed above,
oat requires to be processed to make it safe to consume but
not to such an extent that it loses its nutritional values and
processing become detrimental. A distinction ought to be
made between oat-based foods according to their degree of
processing,123 which will help identify the foods with optimal
health benefits.
Using whole or complex fractions of oat rather than iso-
lated/purified phytochemicals could be profitable for the
industry given that less processing and extracting agents/solu-
tions would be necessary. In order to avoid fluctuations
between batches and to ensure a high quality of the products,
detailed characterisation is fundamental to define the ranges
of bioactivity. These foods also have to be attractive to consu-
mers if the health impacts are to be fully realised, which is
another challenge to the food industry. Further research
should therefore aim at identifying the most active forms of
oat and the combination of nutrients and phytochemicals in
relation to cholesterol levels and risk of cardiovascular disease.
A better characterisation of the structural form of oat
that is ingested and as it progresses through the gastrointesti-
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nal tract is still required to provide valuable information for
the design of healthier food products.
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